Mostrando 2 resultados de: 2
Epirubicin dose and sequential hormonal therapy - Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer
ArticleAbstract: Background The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was dPalabras claves:adjuvant, Breast Cancer, chemotherapy, Clinical trial, Disease outcome, Hormone manipulationAutores:Bliss J.M., Coombes R.C., Faustino R. Pérez-López, Kilburn L.S., Olmos T., Palmieri C., Stebbing J., Tubiana-Mathieu N., Van Bochove A.Fuentes:scopusEpirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group
ArticleAbstract: Purpose: To assess whether the addition of epirubicin (EPI) therapy to prolonged treatment with tamoPalabras claves:Autores:Bliss J.M., Coombes G., Coombes R.C., Faustino R. Pérez-López, Fontaine C., Marty M., Morvan F., Olmos T., Vassilopoulos P., Wils J.A., Woods E.M.Fuentes:scopus